Go Pro
NASDAQ:HCWB

HCW Biologics Q4 2024 Earnings Report

HCW Biologics logo
$1.66 -0.15 (-8.29%)
Closing price 04:00 PM Eastern
Extended Trading
$1.75 +0.09 (+5.42%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCW Biologics EPS Results

Actual EPS
-$19.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$0.40 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Q4 2024
Time
During Market Hours
Conference Call Date
Friday, March 28, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

HCW Biologics' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HCW Biologics Earnings Headlines

HCW Biologics Updates Special Meeting Proxy Materials
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.tc pixel
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB) is a clinical-stage biotechnology company focused on developing immunotherapies for diseases associated with chronic, low-grade inflammation, including cancer and age-related conditions. The company’s approach is designed to restore immune balance by reducing harmful inflammation while enhancing the body’s ability to generate an effective immune response.

HCW Biologics uses its proprietary Tissue-based Optimized Biologics Immunotherapy (TOBI™) platform to create engineered fusion-protein therapeutics. Its lead investigational product, HCW9218, is designed to combine immune-stimulating activity through the interleukin-15 pathway with inhibition of transforming growth factor beta, a signaling protein that can suppress immune responses. The company has evaluated HCW9218 in clinical studies involving oncology and other inflammation-related applications.

HCW Biologics is headquartered in Miramar, Florida, and its programs are primarily in research and clinical development rather than commercial production. The company was founded by immunology researcher Hing Wong, who has served as its chief executive officer and has led the development of its biologics platform and therapeutic pipeline.

View HCW Biologics Profile